Company intelligence / Profile preview

Coherence Biotech

Ownership: Private
Development stage: Other

Overview

Coherence Biotech develops decentralized, easy-to-operate molecular diagnostic solutions and programmable benchtop automation systems that accelerate drug discovery workflows. Their Touchstone DX platform supports rapid, reliable point-of-care molecular testing. The company also offers an all-in-one device that automates complex cell-based assays, bridging computational models with real-world validation to streamline preclinical research and drug development processes.

Modalities: Molecular diagnostics/testsAutomation platforms for in vitro testing and cell-based assays
Industry: Molecular Diagnostics

Partnerships

Engages in outlicensing, collaborative R&D, CDMO/CRO partnerships with biotech/pharma companies using its platforms.

Beyond the preview

Go deeper on Coherence Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coherence Biotech.

Explore the full profile